Prolaris Test from Myriad Genetics Predicts Biochemical Recurrence in Prostate Cancer Patients After Radiation Therapy
November 28, 2012, Myriad Genetics, a leading molecular diagnostic company has developed and presented a new test that will help in the prediction if prostate cancer may likely occur in a patient after he might have undergone external beam radiation therapy (EBRT).
This test is known a Prolaris Test. It measures the cell cycle progression (CCP) genes as a way of predicting the recurrence of the cancer after the treatment. Details of this new test have been highlighted in the article below:
Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA Failure After EBRT,” was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris® test, which measures cell cycle progression (CCP) genes, significantly predicts PSA biochemical recurrence in patients after treatment with external beam radiation therapy (EBRT).
Researchers at Durham VA Medical Center, Duke University School of Medicine, and Myriad Genetics analyzed biopsy specimens from 152 patients with prostate cancer. In this prospectively collected cohort, the Prolaris test was a significant predictor of biochemical recurrence in patients that had undergone radiation treatment (p=0.0017). After adjustment for Gleason score, PSA percent positive cores, and concurrent anti-hormone therapy, the Prolaris test accurately predicted those patients who would benefit from radiation therapy (p=0.034).
“Current approaches to the management of patients with prostate cancer lead to significant under and overtreatment of patients,” said Dr. Stephen Freedland, Durham VA Medical Center and Duke University School of Medicine. “Measurement of the CCP score identifies prostate cancer patients at high risk of progression despite conventional radiation therapy who might be considered for more aggressive treatment regimens.”
Approximately 25% of men who undergo primary radiation therapy will suffer potentially life threatening disease recurrence and progression. The Prolaris test could be used to identify these at-risk patients prior to their initial treatment. These patients may be appropriate candidates for more aggressive combination therapies such as radiation with anti-androgen therapy or chemotherapy.
The clinically important information that Prolaris provides cannot be obtained from currently available clinical parameters. In addition, this is the first Prolaris study that contained a significant number of African American men, a population known to be at especially high risk for aggressive prostate cancer.
Prolaris is a genomic risk stratification test developed to aid physicians in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris is a direct molecular measure of prostate cancer tumor biology. By measuring the expression levels of genes involved with cancer replication, Prolaris is able to more accurately predict disease progression and enable physicians to better define a treatment/monitoring strategy for their patients. Prolaris is significantly more prognostic than currently used clinicopathologic variables and provides unique additional information that can be combined with other clinical factors to make the most accurate prediction of a patient’s cancer aggressiveness and therefore disease progression.
Prolaris has been proven to predict clinical progression in 4 different clinical cohorts, in both pre and post-treatment scenarios. Click here for more details on the Myriads Genetics Test.
So, understanding that you can predict whether a recurrence of prostate cancer can help to doctors prepare for effective treatments ahead.
Myriad Genetics’ Prolaris Test predicts recurrence of cancer of the prostate and will readily help in providing more cure for men afflicted with this condition that is diagnosed in more than 250,000 men in America.
Prevention of recurrence is very important to improve mortality for prostate cancer patients.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Radiation Therapy Options for Prostate Cancer Patients
- How You Can Prevent Prostate Cancer Recurrence
- Proton Beam Therapy and Standard Radiation Therapy – Which Is Better?
- A New Combined Radiation Therapy for Prostate Cancer Is Safer and Offers Lower Risk of Reoccurrence
- Early Hormone Therapy Radiation Prostate Cancer
- Prostate Cancer Recurrence and Symptoms
- Prostate Brachytherapy And IMRT -Intensity Modulated Radiation Therapy
- DNA Test Helps to Predict the Outlook for Patients with Prostate Cancer
- DNA Blood Test to Predict the Life Threatening Prostate Cancer in Patients
- Intensity Modulated Radiation Therapy for Prostrate Cancer (IMRT)
- Prostate Cancer Therapy and Relapse After Radiation Treatment
- Prostate Cancer – Side Effects of Radiation Therapy
- IMRT or Intensity Modulated Radiation Therapy Treatment for Prostate Cancer
- Radiation Therapy Candidates for New Investigational Study On Prostate Cancer Treatment
- Prostate Cancer Hormonal Treatment and Radiation Therapy